EMEA-002238-PIP01-17-M01 - paediatric investigation plan

interferon beta-1a

Key facts

• Active Substance:
  interferon beta-1a
• Therapeutic area:
  Pneumology-allergology
• Decision number:
  P/0096/2021
• PIP number:
  EMEA-002238-PIP01-17-M01
• Pharmaceutical form(s):
  Powder for solution for injection
• Condition(s) / indication(s):
  Treatment of Acute Respiratory Distress Syndrome (ARDS)
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  Faron Pharmaceuticals Ltd.

  E-mail: [e-mail]; Tel: [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  17/03/2021

Decision

P/0096/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for interferon beta-1a (EMEA-002238-PIP01-17-M01)

Reference Number: EMA/144878/2021